Basel Medical Group Ltd

Basel Medical Group Ltd announced its board of directors has approved a 1-for-12 reverse share split, effective June 22, 2026. This move aims to comply with Nasdaq Marketplace Rule 5550(a)(2) requiring a minimum bid price of $1 per share. The total number of outstanding ordinary shares will decrease from approximately 18.7 million to 1.5 million. The shares will continue to trade under the ticker BMGL but with a new CUSIP number.

Basel Medical Group Ltd announced its board of directors has approved a 1-for-12 reverse share split, effective June 22, 2026. This action aims to enable the Company to regain compliance with Nasdaq's minimum bid price requirement of $1 per share. The reverse split will reduce the number of outstanding ordinary shares from approximately 18.79 million to 1.57 million, with no fractional shares being issued.

Basel Medical Group Ltd announced the appointment of Mr. Neo Chun How Alton as its new interim Chief Financial Officer, effective June 2, 2026. Mr. Neo replaces Ms. Jianing Lu, who resigned from the position. Mr. Neo brings extensive experience in corporate leadership and financial management, having previously served as deputy CEO of InCorp Global's Singapore operations.